[go: up one dir, main page]

CY1105211T1 - Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη - Google Patents

Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη

Info

Publication number
CY1105211T1
CY1105211T1 CY20061101267T CY061101267T CY1105211T1 CY 1105211 T1 CY1105211 T1 CY 1105211T1 CY 20061101267 T CY20061101267 T CY 20061101267T CY 061101267 T CY061101267 T CY 061101267T CY 1105211 T1 CY1105211 T1 CY 1105211T1
Authority
CY
Cyprus
Prior art keywords
melagatran
receptor antagonist
drug combinations
combinations involving
involving
Prior art date
Application number
CY20061101267T
Other languages
English (en)
Inventor
John Dixon
Robert Humphries
Gavin Jarvis
Ian Kirk
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1105211T1 publication Critical patent/CY1105211T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει καινοτόμους φαρμακευτικούς συνδυασμούς και τη χρήση τους στην αντιθρομβωτική θεραπεία.
CY20061101267T 1999-12-01 2006-09-05 Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη CY1105211T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904377A SE9904377D0 (sv) 1999-12-01 1999-12-01 Pharmaceutical combinations
PCT/SE2000/002378 WO2001039781A1 (en) 1999-12-01 2000-11-29 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
CY1105211T1 true CY1105211T1 (el) 2010-03-03

Family

ID=20417947

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101267T CY1105211T1 (el) 1999-12-01 2006-09-05 Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη

Country Status (33)

Country Link
US (2) US20030032618A1 (el)
EP (2) EP1719526A3 (el)
JP (1) JP2003515565A (el)
KR (1) KR100785953B1 (el)
CN (1) CN1402639A (el)
AR (1) AR033658A1 (el)
AT (1) ATE332698T1 (el)
AU (1) AU781691B2 (el)
BR (1) BR0016043A (el)
CA (1) CA2391161C (el)
CO (1) CO5271717A1 (el)
CY (1) CY1105211T1 (el)
CZ (1) CZ300925B6 (el)
DE (1) DE60029340T2 (el)
DK (1) DK1237559T3 (el)
EE (1) EE05127B1 (el)
ES (1) ES2267591T3 (el)
HK (1) HK1047893A1 (el)
HU (1) HU230890B1 (el)
IL (1) IL149495A0 (el)
IS (1) IS2841B (el)
MX (1) MXPA02004871A (el)
MY (1) MY128896A (el)
NO (1) NO331215B1 (el)
NZ (2) NZ530058A (el)
PT (1) PT1237559E (el)
RU (1) RU2242232C2 (el)
SE (1) SE9904377D0 (el)
SI (1) SI1237559T1 (el)
SK (1) SK288707B6 (el)
TW (1) TWI251491B (el)
WO (1) WO2001039781A1 (el)
ZA (1) ZA200203707B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
CN101253179B (zh) * 2005-09-21 2010-12-29 株式会社钟根堂 S-氯吡格雷的树脂酸盐复合物及其制备方法
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2011060066A2 (en) 2009-11-11 2011-05-19 The Medicines Company Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2827154C (en) 2011-02-09 2020-12-29 The Medicines Company Methods for treating pulmonary hypertension
CA2904523C (en) 2013-03-09 2024-01-09 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8826448D0 (en) * 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
EP0508687B1 (en) * 1991-04-06 1995-09-13 Astra Pharmaceuticals Limited ATP analogues
TW326045B (en) * 1993-02-10 1998-02-01 Astra Pharma Prod N-alkyl-2-substituted ATP analogues the invention relates to a compound of formula (I) and its pharmaceutically acceptable salt which can be used for inhibition of platelet aggregation.
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
CN1069321C (zh) * 1995-07-11 2001-08-08 阿斯特拉曾尼卡有限公司 新的血小板凝集抑制剂
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
CA2532805A1 (en) * 2003-07-16 2005-01-27 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
ES2267591T3 (es) 2007-03-16
RU2242232C2 (ru) 2004-12-20
WO2001039781A1 (en) 2001-06-07
ATE332698T1 (de) 2006-08-15
RU2002117296A (ru) 2004-01-20
NZ530058A (en) 2005-04-29
IS2841B (is) 2013-08-15
HU230890B1 (hu) 2018-12-28
PT1237559E (pt) 2006-10-31
CZ20021887A3 (cs) 2002-11-13
BR0016043A (pt) 2002-07-23
CN1402639A (zh) 2003-03-12
KR100785953B1 (ko) 2007-12-14
AR033658A1 (es) 2004-01-07
NO20022606D0 (no) 2002-05-31
NZ518904A (en) 2004-02-27
JP2003515565A (ja) 2003-05-07
DE60029340D1 (de) 2006-08-24
US20030032618A1 (en) 2003-02-13
KR20020069201A (ko) 2002-08-29
MY128896A (en) 2007-02-28
HK1047893A1 (en) 2003-03-14
EE05127B1 (et) 2009-02-16
AU1910901A (en) 2001-06-12
CA2391161C (en) 2010-10-05
TWI251491B (en) 2006-03-21
EP1719526A2 (en) 2006-11-08
HUP0203585A3 (en) 2005-01-28
SK7502002A3 (en) 2003-02-04
CO5271717A1 (es) 2003-04-30
EE200200271A (et) 2003-06-16
SE9904377D0 (sv) 1999-12-01
NO20022606L (no) 2002-07-11
CZ300925B6 (cs) 2009-09-09
EP1237559B1 (en) 2006-07-12
MXPA02004871A (es) 2002-08-30
US20060270607A1 (en) 2006-11-30
EP1237559A1 (en) 2002-09-11
SI1237559T1 (sl) 2007-02-28
ZA200203707B (en) 2003-10-29
EP1719526A3 (en) 2007-04-25
PL355841A1 (en) 2004-05-17
NO331215B1 (no) 2011-11-07
IL149495A0 (en) 2004-03-28
DK1237559T3 (da) 2006-10-30
IS6398A (is) 2002-05-27
HUP0203585A2 (hu) 2003-03-28
DE60029340T2 (de) 2007-07-19
AU781691B2 (en) 2005-06-09
SK288707B6 (sk) 2019-10-02
CA2391161A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
DK1036059T3 (da) Adamantanderivater
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
BR9916857A (pt) 4 heteroaril diarilaminas
IS7431A (is) Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða
DK1406633T3 (da) Forbedret lægemiddeltilførsel i transdermale systemer
DE60016271D1 (de) Medikamentenzuführvorrichtung
NO20002785L (no) Adamantanderivater
ATE320799T1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
ATE266422T1 (de) Pharmazeutische hydrogelformulierungen, vorrichtungen zur arzneistoffabgabe und verfahren
DE69812089D1 (de) Pharmazeutische omeprazol-formulierung
ATE312602T1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
ATE548029T1 (de) Wirkstoffabgabevorrichtung mit verzögerter freisetzung
ATE238776T1 (de) Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
ATE285754T1 (de) Pharmazeutische zusammensetzung mit lyophilisierten lyposomen welche einen unlöslichen aktiven wirkstoff einschliessen, verfahren zu dessen herstellung
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
DE69941825D1 (de) Arzneistoffhaltiger kaugummi, dessen herstellungsverfahren und so erhaltene tablette
ATE258045T1 (de) Verfahren zu herstellung von pulverförmigen solubilisationshilfsstoffen für feste pharmazeutische darreichungsformen
DK0983361T3 (da) Bakterielle pheromoner og anvendelser deraf
IT1318509B1 (it) Polimeri reticolati, utili per uso farmaceutico, medicale e cosmetico.
TR200103219T2 (tr) Nöropatik ağrının iyileştirilmesinde kullanım için aroil aminoasil piroller
CY1105624T1 (el) Αντιγλαυκωματικο μεσο και χρηση αυτου